Details of the Drug
General Information of Drug (ID: DMOY9J8)
Drug Name |
(-)-norfenfluramine
|
||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
l-norfenfluramine; 37577-22-3; (R)-1-(3-TRIFLUOROMETHYLPHENYL)-2-AMINOPROPANE; UNII-ODG984O60W; ODG984O60W; (2R)-1-[3-(trifluoromethyl)phenyl]propan-2-amine; Benzeneethanamine, a-methyl-3-(trifluoromethyl)-, (; (R)-Norfenfluramin; (R)-Norfenfluramine; Norfenfluramine, (R)-; GTPL217; (R)-1-(3-(trifluoromethyl)phenyl)propan-2-amine; SCHEMBL895637; CHEMBL250881; BDBM85598; CTK4H8426; MLBHFBKZUPLWBD-SSDOTTSWSA-N; CHEBI:125653; ZINC2039145; PDSP1_000697; PDSP2_000687; PDSP1_001422; AKOS030231006
|
||||||||||||||||||||||
Indication |
|
||||||||||||||||||||||
Drug Type |
Small molecular drug
|
||||||||||||||||||||||
Structure | |||||||||||||||||||||||
3D MOL is unavailable | 2D MOL | ||||||||||||||||||||||
#Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 203.2 | |||||||||||||||||||||
Logarithm of the Partition Coefficient (xlogp) | 2.5 | ||||||||||||||||||||||
Rotatable Bond Count (rotbonds) | 2 | ||||||||||||||||||||||
Hydrogen Bond Donor Count (hbonddonor) | 1 | ||||||||||||||||||||||
Hydrogen Bond Acceptor Count (hbondacc) | 4 | ||||||||||||||||||||||
Chemical Identifiers |
|
||||||||||||||||||||||
Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
The Studied Disease | Discovery agent | |||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ICD Disease Classification | N.A. | |||||||||||||||||||||||
|
||||||||||||||||||||||||
Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||
References